Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 9/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.48 |
| ▸ | LDLR | P01130 | 2/20 | 0.48 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.48 |
| ▸ | KLHL20 | Q9Y2M5 | 1/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25455205 | 0.97 | ITGB3 (0.52) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25455512 | 0.97 | KLKB1 (0.50) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25455193 | 0.96 | ITGB3 (0.52) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25455514 | 0.96 | KLKB1 (0.50) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25457461 | 0.96 | KLKB1 (0.49) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25455401 | 0.94 | KLKB1 (0.52) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25455264 | 0.94 | KLKB1 (0.52) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25455236 | 0.94 | PLAU (0.52) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25455263 | 0.94 | KLKB1 (0.52) | KLKB1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL25457240 | 0.94 | PLAU (0.51) | KLKB1ITGB3ITGB1ITGAVITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | QUANTUM INTELLIGENCE CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | QUANTUM INTELLIGENCE CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | ITGB7, ITGAM, ITGA4 | KLKB1 1100/4885ITGB3 22/4885ITGB1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.